Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 5,000 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the director now owns 16,641 shares in the company, valued at $832,050. This trade represents a 23.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total value of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $1.52 during trading hours on Friday, reaching $43.60. The company had a trading volume of 803,345 shares, compared to its average volume of 651,469. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -12.11 and a beta of 1.85. The stock has a fifty day moving average of $46.35 and a 200-day moving average of $46.46.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent analyst reports. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. State Street Corp boosted its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the last quarter. Geode Capital Management LLC raised its stake in Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after purchasing an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience in the 3rd quarter valued at about $43,992,000. Wellington Management Group LLP grew its stake in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares during the period. Finally, Fred Alger Management LLC increased its holdings in shares of Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after buying an additional 112,272 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.